Some people are turning to nicotine gum and patches to treat long COVID brain fog
Some people with long COVID are turning to an unlikely remedy: nicotine gum and patches. Though typically used to quit smoking, nicotine is now being explored as a possible way to ease symptoms such as brain fog and fatigue.
One such case, detailed in a recent article in Slate, describes a woman who found significant relief from debilitating brain fog after trying low-dose nicotine gum. Her experience, while anecdotal, aligns with findings from a small but interesting study from Germany.
The study involved four participants suffering from symptoms related to long COVID. The researcher administered low-dose nicotine patches once daily and noticed marked improvements in the participants' symptoms. Tiredness, weakness, shortness of breath and trouble with exercise rapidly improved – by day six at the latest.
For those who had lost their sense of taste or smell, it took longer, but these senses came back fully within 16 days. Although it's not possible to draw definitive conclusions on cause and effect from such a small study, the results could pave the way for larger studies.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
While some people slowly recover from COVID, others remain unwell for years, especially those who became sick before vaccines were available. Between 3% and 5% of people continue to experience symptoms months, and sometimes even years, after the initial infection. In the UK, long COVID affects around 2.8% of the population.
Brain fog and other neurological symptoms of long COVID are thought to result from a combination of factors – including inflammation, reduced oxygen to the brain, vascular damage and disruption to the blood-brain barrier. Research continues as there is still a lot we don't know about this condition.
The researcher in the German study thinks that long COVID symptoms, such as fatigue, brain fog and mood changes, might partly be due to problems with a brain chemical called acetylcholine, a neurotransmitter. This chemical is important for many functions in the body, including memory, attention and regulating mood.
Normally, acetylcholine works by attaching to special 'docking sites' on cells called nicotinic acetylcholine receptors, which help send signals in the brain and nervous system. But the COVID virus may interfere with these receptors, either by blocking them or disrupting how they work. When this happens, the brain may not be able to send signals properly, which could contribute to the mental and physical symptoms seen in long COVID.
So why would nicotine potentially be useful? Nicotine binds to the same receptors and might help restore normal signalling, but the idea that it displaces the virus directly is still speculative.
Nicotine is available in different forms, such as patches, gum, lozenges and sprays. Using nicotine through the skin, for example, with a patch, keeps the amount in the blood steady without big spikes. Because of this, people in the study didn't seem to develop a dependence on it.
Chewing nicotine gum or using a lozenge can cause spikes in nicotine levels, since the nicotine is absorbed gradually through the lining of the mouth. But unlike a patch, which delivers a steady dose, the user has more control over how much nicotine they take in when using gum or lozenges.
There are mixed results on the effectiveness of nicotine on cognitive functions such as memory and concentration. But most studies agree that it can enhance attention. Larger studies are needed to gauge the effectiveness of nicotine specifically for long COVID symptoms.
Despite its benefits, nicotine is not without risks. Even in gum or patch form, it can cause side-effects like nausea, dizziness, increased heart rate and higher blood pressure.
Some of these stimulant effects on heart rate may be useful for people with long COVID symptoms such as exercise intolerance. But this needs to be closely monitored. Long-term use may also affect heart health. For non-smokers, the risk of developing a nicotine dependency is a serious concern.
So are there any options to treat long COVID symptoms?
There are some studies looking at guanfacine in combination with N-acetylcysteine, which have shown improvement in brain fog in small groups of people. There has been at least one clinical trial exploring nicotine for mild cognitive impairment in older adults, though not in the context of long COVID. Given that anecdotal reports and small studies continue to draw attention, it is likely that targeted trials are in development.
The main recommendations by experts are to implement lifestyle measures. Slowly increasing exercise, having a healthy diet, avoiding alcohol, drugs and smoking, sleeping enough, practising mindfulness and doing things that stimulate the brain are all thought to help brain fog.
For those grappling with long COVID or persistent brain fog, the idea of using nicotine patches or gum might be tempting. But experts caution against self-medicating with nicotine. The lack of standardised dosing and the potential for addiction and unknown long-term effects make it a risky experiment.
While nicotine isn't a cure and may carry real risks, its potential to ease long COVID symptoms warrants careful study. For now, those battling brain fog should approach it with caution – and always under medical supervision. What's clear, though, is the urgent need for more research into safe, effective treatments for the lingering effects of COVID.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Dipa Kamdar does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
an hour ago
- New York Times
Did Baby Talk Give Rise to Language?
If you've ever cooed at a baby, you have participated in a very special experience. Indeed, it's an all but unique one: Whereas humans constantly chatter to their infants, other apes hardly ever do so, a new study reveals. 'It's a new feature that has evolved and massively expanded in our species,' said Johanna Schick, a linguist at the University of Zurich and an author of the study. And that expansion, Dr. Schick and her colleagues argue, may have been crucial to the evolution of language. Other mammals can bark, meow, roar and hoot. But no other species can use a set of sounds to produce words, nor build sentences with those words to convey an infinite variety of meaning. To trace the origin of our gift of language, researchers often study apes, our closest living relatives. These studies hint that some of the ingredients of language had already evolved in the ancestors we share with living apes, which lived millions of years ago. Chimpanzees can make dozens of distinct calls, for example, which they can join into pairs to communicate new things. Building meaning from smaller units is what lets us create sentences from words. Humans and apes are similar in another way: Their babies need time to learn how to make sounds like adults. Scientists have done much more research into how human infants develop language than into how wild baby apes learn to make calls. One striking feature of humans is the way that adults speak to young children. Baby talk — known to scientists as infant-directed speech — often features repeated words, an exaggerated stress on syllables and a high, singsong tone. This distinctive pattern is very effective at grabbing the attention of young children — even when they're too young to understand the meaning of the words that adults are saying. It's possible that children pay attention to infant-directed speech because it helps them learn some of the basic features of language. Want all of The Times? Subscribe.
Medscape
2 hours ago
- Medscape
NICE Backs Leadless Pacemakers for Some Heart Patients
The National Institute for Health and Care Excellence (NICE) has provisionally recommended leadless cardiac pacemaker implantation for patients with bradyarrhythmias who require single-chamber pacing. In draft guidance, NICE said there was insufficient evidence to support their use for dual-chamber pacing outside of research settings. Benefits Over Traditional Pacemakers The recommendation is based on an evidence review involving over one million patients across multiple studies. These included a randomised controlled trial, four systematic reviews with meta-analyses, five registry studies, four prospective studies, and two retrospective studies. Leadless pacemakers were found to be effective at detecting abnormal heart rhythms, restoring normal pacing, and improving quality of life. Unlike conventional transvenous pacemakers (TVPs), they do not require a chest incision, reducing the risk of infection and other complications, the regulator noted. 'The evidence demonstrates that leadless pacemakers can effectively regulate heart rhythm while reducing the risk of complications associated with traditional pacemakers, particularly infections and lead-related issues,' said Dr Anastasia Chalkidou, HealthTech programme director at NICE. How Leadless Pacemakers Work Bradyarrhythmias, which affect around 1 in 1000 people are typically treated with TVPs. These devices consist of a subcutaneous pacemaker box and leads that connect to the heart. For single-chamber leadless pacemakers, the proximal end is attached to a deflectable delivery catheter system. It is usually inserted percutaneously through the femoral or jugular vein using an introducer sheath. It is then moved into the right atrium, through the tricuspid valve, and into the right ventricle. Dual-chamber systems, which are still under evaluation, involve placing two devices — one in the right atrium and another in the right ventricle — during a single procedure. NICE highlighted that TVPs are known to carry risks, including lead failure and generator-related complications. Leadless pacemaker implantation may be preferable for patients with a history of device infection, endocarditis, immunosuppression, limited vascular access, or high infection risk. Call for Further Research While the draft guidance supports leadless pacemakers for single-chamber pacing, NICE said that more evidence is needed before endorsing their wider use. This includes research on patient selection — such as age, comorbidities, and the underlying cause of bradyarrhythmia — as well as data on implantation sites and clinical outcomes. Long-term durability of leadless devices also remains an area for investigation. 'The incidence of bradyarrhythmias increases with age, making this guidance particularly relevant to our ageing population,' said Professor Tom Clutton-Brock, chair of NICE's interventional procedures advisory committee. The draft guidance is open for public consultation until 23 July 2025. The advisory committee will meet again on 11 September 2025 to review feedback and finalise recommendations.
Health Line
2 hours ago
- Health Line
Anaplastic Astrocytoma
This rare, aggressive type of cancerous brain tumor can cause headaches, seizures, and changes in behavior or cognitive (thinking) function. Treatment involves surgery combined with radiation and chemotherapy. Astrocytomas are a type of brain tumor. They develop in star-shaped brain cells called astrocytes, which form part of the tissue that protects the nerve cells in your brain and spinal cord. Astrocytomas are classified by their grade — grade 1 and 2 astrocytomas grow slowly, while grade 3 and 4 astrocytomas grow faster and more aggressively. An anaplastic astrocytoma is a grade 3 astrocytoma. While rare, this type of cancerous tumor can be very serious without treatment. Keep reading to learn more about anaplastic astrocytomas, including their symptoms and the survival rates of people who have them. What are the symptoms? The symptoms of an anaplastic astrocytoma can vary based on exactly where the tumor is, but generally include: headaches lethargy or drowsiness nausea or vomiting behavioral changes memory loss seizures vision problems coordination and balance problems What causes it? Researchers aren't sure what causes anaplastic astrocytomas. However, they may be associated with: genetic abnormalities immune system abnormalities environmental factors, such as exposure to UV rays and certain chemicals lifestyle factors, such as diet or stress People with certain genetic disorders, such as neurofibromatosis type I (NF1), Li-Fraumeni syndrome, or tuberous sclerosis, have a higher risk of developing anaplastic astrocytoma. If you've had radiation therapy on your brain, you may also be at a higher risk. How is it diagnosed? Anaplastic astrocytomas are rare, so your doctor will start by discussing your medical history and performing a physical exam to identify any other possible causes of your symptoms. They may also use a neurological exam to see how your nervous system is working. This usually involves testing your balance, coordination, and reflexes. You may be asked to answer some basic questions so they can evaluate your speech and mental clarity. If your doctor thinks you may have a tumor, they'll likely use imaging such as an MRI scan or CT scan to examine a picture of your brain. If you do have an anaplastic astrocytoma, these images will also show its size and exact location. In some cases, doctors use a PET scan or SPECT scan. These metabolic scans look at cellular activity in the brain rather than the detailed anatomy seen on an MRI. These tests can sometimes be helpful for assessing tumor cells. A biopsy may also be part of the diagnostic process and can involve removing as much of the tumor as possible. How is it treated? There are several options for treating an anaplastic astrocytoma, depending on the size, location, and grade of the tumor. Surgery Surgery is usually the first step in treating an anaplastic astrocytoma. In some cases, your doctor may be able to remove all or as much of the tumor as possible. However, anaplastic astrocytomas may grow in areas of the brain that are not safe or accessible for surgery, so your doctor may only be able to safely remove part of the tumor. Tumor cells that remain because they were not identified or were surgically inaccessible can grow quickly after surgery. Chemotherapy and radiation therapy If your tumor can't be removed with surgery or was only partially removed, you may need follow-up treatment. Radiation therapy destroys cells, especially rapidly dividing cancer cells. This will help shrink the tumor or destroy some or all of the cells that weren't removed during surgery. Anticancer drugs are referred to as chemotherapy and may be used with or after radiation therapy to continue treatment. Some people may also be treated with: epilepsy medication hydrocephalus treatment steroids physical therapy Survival rate and life expectancy According to the American Cancer Society, the 5-year relative survival rate for people with an anaplastic astrocytoma is as follows: 58% for those ages 22 to 44 29% for those ages 45 to 54 15% for those ages 55 to 64 The relative survival rate suggests how long someone with a condition may live after their diagnosis compared to those without the condition of the same race, sex, and age over a specific time. This is different from the overall survival rate, which is a percentage of people still alive for a specific time after diagnosis of a condition. It's most important to remember that these figures are estimates, and everyone is different. You can talk with your doctor about your specific condition. Several factors can affect your survival rate, including: the size, location, and grade of your tumor whether the tumor was completely or partially removed with surgery whether the tumor is new or recurring your overall health Your doctor can give you a better idea of your outlook based on these factors. The takeaway Anaplastic astrocytoma is a rare, aggressive type of cancerous brain tumor. Symptoms can vary but often include headache, seizures, and changes in behavior or cognitive function.
